Pipeline

Our pipeline of immune-modulating, clinical-stage product candidates are based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation.

Program & Target	Therapeutic Area	Preclinical	Rights
Rilonacept* IL-1α & IL-1β	Recurrent Pericarditis**	End Phase 3	Worldwide (excluding the Middle East and North Africa)
Mavrilimumab*** GM-CSFRα	Giant Cell Arteritis	Phase 2	Worldwide
Mavrilimumab*** GM-CSFRα	COVID-19 Pneumonia & Hyperinflammation	Phase 2	Worldwide
Vixarelimab OSMRβ	Prurigo Nodularis	Phase 2	Worldwide
Vixarelimab OSMRβ	Diseases Characterized by Chronic Pruritus	Phase 2	Worldwide
KPL-404 CD40	T-Cell Dependent, B-Cell–Mediated Indications	Phase 1	Worldwide

*The FDA granted Breakthrough Therapy designation to rilonacept for recurrent pericarditis in 2019 and Orphan Drug designation to rilonacept for pericarditis in 2020.
**Data from RHAPSODY, a pivotal Phase 3 trial of rilonacept in recurrent pericarditis, were reported in June 2020. Per the license agreement with Regeneron Pharmaceuticals, Inc, ownership of the rilonacept BLA will transfer to Kiniksa. Kiniksa expects to file an sBLA with the FDA by the end of 2020.
*** The FDA granted Orphan Drug designation to mavrilimumab for giant cell arteritis in 2020.

Every Second Counts!